|
Resources from www.pharmigene.com
Since the completion of the human genome sequences, personalized medicine based on individual’s genomic profiles is now possible. For example, scientists have identified that patients with a specific genetic marker can have over thousand folds increase their chance of severe adverse reason to specific drug. Using a companion genetic test to offer a safer and more effective drug for patients has become a reality.
HLA-B*1502 allele is found to have a strong linkage with Carbamazepine induced Steven-Johnson Syndrome (SJS) and Toxic Epidermal necrolysis (TEN) in Asian descendents. HLA-B*1502 allele is located in human chromosome 6 and belongs to human leukocyte antigen. The results of PG-1502 DNA detection can be used as an aid for the clinicians to identify the patients with the presence of HLA-B*1502 allele that may pose a greater risk of carbamazepine (CBZ) induced SJS/TEN.
HLA-B*5801 allele is found having a strong linkage with Allopurinol induced server cutaneous adverse reactions (SCARs) which include Hypersensitivity syndrome (HSS), Steven-Johnson Syndrome (SJS) and Toxic Epidermal necrolysis (TEN). HLA-B*5801 allele is located in human chromosome 6 and is a genotype of human leukocyte antigen. The result of HLA-B*5801 allele detection can be a reference for using Allopurinol in clinical setting.
Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thromobosis, atrial fibrillation or mechanical heart valve replacement. However, warfarin treatment is problematic because the dose requirement for warfarin is highly variable. Incorporation of VKORC1-1639 and CYP2C9 genotype, age, body weight and gender can estimate the warfarin dose.
| 
